Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254621 | 0.90 | HASPIN (0.42) | HASPINSMN1; SMN2NPC1RAB9ALMNA | |
| Nitrous Acid SCHEMBL28989822 | 0.84 | HASPIN (0.39) | HASPINSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL21274047 | 0.83 | HASPIN (0.40) | HASPINSMN1; SMN2POLBLMNAMAPK1 | |
| SCHEMBL1829942 | 0.81 | HASPIN (0.44) | HASPINSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL11856675 | 0.77 | TLR7 (0.44) | HASPINSMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL7480837 | 0.76 | TLR7 (0.43) | HASPINSMN1; SMN2NPC1RAB9AGPR84 | |
| SCHEMBL28989820 | 0.75 | HASPIN (0.38) | HASPINSMN1; SMN2LMNA | |
| SCHEMBL17594559 | 0.74 | HASPIN (0.35) | HASPINSMN1; SMN2LMNA | |
| SCHEMBL1760914 | 0.73 | KMT2A (0.46) | HASPINPOLBLMNAMAPK1ALPL | |
| SCHEMBL29121475 | 0.73 | CXCR2 (0.36) | SMN1; SMN2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3955929-B1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | UNIV LIEGE (BE) | 2024-05-15 | — | — | EP | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | Université de Liège (BE) | 2022-09-06 | — | — | US | disclosed |
| EP-3955929-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2022-02-23 | — | — | EP | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| CN-113329753-A | Novel pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, contaminations and dirt | 列日大学 | 2021-08-31 | — | — | CN | disclosed |
| US-20210061804-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | Université de Liège (BE) | 2021-03-04 | — | — | US | disclosed |
| US-20210061804-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | Université de Liège (BE) | 2021-03-04 | — | — | US | disclosed |
| EP-3752506-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | Universite De Liege (BE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020212553-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212553-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2020-10-22 | — | — | WO | disclosed |
| CN-111386271-A | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019158655-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITE DE LIEGE (BE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019158655-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITE DE LIEGE (BE) | 2019-08-22 | — | — | WO | disclosed |
| US-3969101-A | 4,6-DIAMINO-5-NITRO-2-ALKYLTHIO-PYRIMIDINES | CIBA-GEIGY CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061804-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | TYMP, TYMS, UMPS | HASPIN 2336/4885SMN1; SMN2 4665/4885NPC1 4263/4885 |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | HASPIN 2047/4885SMN1; SMN2 4821/4885NPC1 3539/4885 |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | PIGS, TYMP, TYMS | HASPIN 2047/4885SMN1; SMN2 4821/4885NPC1 3539/4885 |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | TYMP, TYMS, UMPS | HASPIN 2336/4885SMN1; SMN2 4665/4885NPC1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.